Standout Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 ... 2011 2026 2016 2021 4.1k
  1. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (2018)
    Stephen D. Wiviott, Itamar Raz et al. New England Journal of Medicine
  2. Standardized Bleeding Definitions for Cardiovascular Clinical Trials (2011)
    Roxana Mehran, Sunil V. Rao et al. Circulation
  3. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (2013)
    Benjamin M. Scirica, Deepak L. Bhatt et al. New England Journal of Medicine
  4. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (2018)
    Deepak L. Bhatt, Philippe Gabríel Steg et al. New England Journal of Medicine
  5. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials (2018)
    Thomas A. Zelniker, Stephen D. Wiviott et al. The Lancet
  6. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes (2017)
    Philip R. Schauer, Deepak L. Bhatt et al. New England Journal of Medicine
  7. Guidelines for the Early Management of Adults With Ischemic Stroke (2007)
    Harold P. Adams, Gregory del Zoppo et al. Stroke
  8. Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes (2012)
    Philip R. Schauer, Sangeeta R. Kashyap et al. New England Journal of Medicine
  9. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes (2014)
    Philip R. Schauer, Deepak L. Bhatt et al. New England Journal of Medicine
  10. A Controlled Trial of Renal Denervation for Resistant Hypertension (2014)
    Deepak L. Bhatt, David E. Kandzari et al. New England Journal of Medicine
  11. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome (2011)
    Jessica L. Mega, Eugene Braunwald et al. New England Journal of Medicine
  12. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  13. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis (2006)
    Deepak L. Bhatt JAMA
  14. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis (2007)
    Philippe Gabríel Steg, Deepak L. Bhatt et al. JAMA
  15. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials (2013)
    Viktoria Gloy, Matthias Briel et al. BMJ
  16. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (2022)
    Steven R. Ytterberg, Deepak L. Bhatt et al. New England Journal of Medicine
  17. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (2017)
    Christopher P. Cannon, Deepak L. Bhatt et al. New England Journal of Medicine
  18. Clopidogrel with or without Omeprazole in Coronary Artery Disease (2010)
    Deepak L. Bhatt, Byron Cryer et al. New England Journal of Medicine
  19. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease (2020)
    Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine
  20. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis (2009)
    Shanshan Chu, Richard C. Becker et al. Journal of Thrombosis and Haemostasis
  21. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction (2017)
    Kevin Shah, Haolin Xu et al. Journal of the American College of Cardiology
  22. Guidelines for the Early Management of Adults With Ischemic Stroke (2007)
    Harold P. Adams, Gregory del Zoppo et al. Circulation
  23. Sleep Duration and Quality: Impact on Lifestyle Behaviors and Cardiometabolic Health: A Scientific Statement From the American Heart Association (2016)
    Marie‐Pierre St‐Onge, Michael A. Grandner et al. Circulation
  24. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials (2017)
    Francesco Costa, David van Klaveren et al. The Lancet
  25. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2008)
    Deepak L. Bhatt, James M. Scheiman et al. Circulation
  26. Variability in platelet responsiveness to clopidogrel among 544 individuals (2005)
    Victor L. Serebruany, Steven R. Steinhubl et al. Journal of the American College of Cardiology
  27. Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction (2012)
    Benjamin A. Steinberg, Xin Zhao et al. Circulation
  28. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial (2014)
    Benjamin M. Scirica, Eugene Braunwald et al. Circulation
  29. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis (2010)
    Deepak L. Bhatt, Kim A. Eagle et al. JAMA
  30. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus (2019)
    Thomas A. Zelniker, Stephen D. Wiviott et al. Circulation
  31. Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke (2011)
    Gregg C. Fonarow, Eric E. Smith et al. Circulation
  32. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019)
    Brian A. Ference, John J.P. Kastelein et al. JAMA
  33. Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction (2019)
    Sameer Arora, George A. Stouffer et al. Circulation
  34. Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative (2014)
    Gregg C. Fonarow, Xin Zhao et al. JAMA
  35. Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes (2019)
    Alexander C. Flint, Carol Conell et al. New England Journal of Medicine
  36. Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction (2014)
    Thomas M. Maddox, Maggie A. Stanislawski et al. JAMA
  37. Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents (2012)
    Sripal Bangalore, Sunil Kumar et al. Circulation
  38. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease (2019)
    Subodh Verma, C. David Mazer et al. Circulation
  39. Diagnosis and Treatment of Acute Coronary Syndromes (2022)
    Deepak L. Bhatt, Renato D. Lópes et al. JAMA
  40. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death (2015)
    Matthew A. Cavender, Philippe Gabríel Steg et al. Circulation
  41. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus (2020)
    Thomas A. Zelniker, Marc P. Bonaca et al. Circulation
  42. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study (2016)
    Emmanuelle Vidal‐Petiot, Ian Ford et al. The Lancet
  43. Adaptive Designs for Clinical Trials (2016)
    Deepak L. Bhatt, Cyrus R. Mehta New England Journal of Medicine
  44. Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine (2017)
    Steven D. Weisbord, Martin Gallagher et al. New England Journal of Medicine
  45. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials (2023)
    Paul M. Ridker, Deepak L. Bhatt et al. The Lancet
  46. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial (2020)
    Matthew J. Budoff, Deepak L. Bhatt et al. European Heart Journal
  47. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid (2020)
    R. Preston Mason, Peter Libby et al. Arteriosclerosis Thrombosis and Vascular Biology
  48. Targeting cardiovascular inflammation: next steps in clinical translation (2020)
    Patrick R. Lawler, Deepak L. Bhatt et al. European Heart Journal
  49. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease (2018)
    Sonia S. Anand, François Caron et al. Journal of the American College of Cardiology
  50. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease (2019)
    Michael C. Honigberg, Seyedeh M. Zekavat et al. JAMA
  51. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (2023)
    Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine
  52. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis (2021)
    Safi U. Khan, Ahmad Naeem Lone et al. EClinicalMedicine
  53. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension (2022)
    Mason W. Freeman, Yuan‐Di C. Halvorsen et al. New England Journal of Medicine
  54. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance (2022)
    Christina Charles‐Schoeman, Maya H Buch et al. Annals of the Rheumatic Diseases
  55. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  56. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations (2024)
    Aeron Small, Giorgio Melloni et al. JAMA Cardiology
  57. Exposome in ischaemic heart disease: beyond traditional risk factors (2024)
    Rocco Antonio Montone, Massimiliano Camilli et al. European Heart Journal

Immediate Impact

4 from Science/Nature 154 standout
Sub-graph 1 of 16

Citing Papers

Rheumatoid Arthritis — Common Origins, Divergent Mechanisms
2023 Standout
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
11 intermediate papers

Works of Deepak L. Bhatt being referenced

Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
2014 Standout
Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes
2012 Standout
and 11 more

Author Peers

Author Last Decade Papers Cites
Deepak L. Bhatt 55509 38853 22590 2.0k 103.4k
Salim Yusuf 104588 28566 23902 1.3k 156.2k
Paul M. Ridker 37641 40769 23448 811 127.8k
Stuart Pocock 34883 31770 15196 569 137.2k
Valentı́n Fuster 52301 33107 6421 1.3k 98.0k
Gregg C. Fonarow 76391 17156 9723 1.8k 109.2k
William B. Kannel 69673 22477 25140 475 125.2k
Philippe Gabríel Steg 54884 29325 9558 1.1k 74.8k
Daniel Levy 88384 24628 18947 807 138.9k
John J.V. McMurray 84097 22055 29299 1.5k 126.4k
Christopher P. Cannon 37120 27182 13675 869 65.6k

All Works

Loading papers...

Rankless by CCL
2026